Skip to Main Content

Paper Details

Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
J Thorac Oncol
1
2023
ADAURA, EGFR, EGFR-Mutated NSCLC, EGFR-mutated NSCLC, Osimertinib, Patients, Stomatitis, diarrhea, interstitial lung disease, osimertinib, patients
Author NameAffiliation
Thomas JohnPeter MacCallum Cancer Centre, The University of Melbourne
Jonathan W GoldmanDavid Geffen School of Medicine at University of California Los Angeles
Jonathan W GoldmanDavid Geffen School of Medicine at University of California Los Angeles
Frances A ShepherdUniversity Health Network, Princess Margaret Cancer Centre and the University of Toronto
Roy S HerbstYale School of Medicine and Yale Cancer Center
  • 1 - 5

Datasets

Release 1.2